

Serena Di Cosimo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4629744/publications.pdf>

Version: 2024-02-01

211
papers

7,893
citations

76326

40
h-index

53230

85
g-index

220
all docs

220
docs citations

220
times ranked

12345
citing authors

#	ARTICLE	IF	CITATIONS
1	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2012, 379, 633-640.	13.7	1,165
2	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 628-638.	6.3	769
3	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. <i>Cancer Research</i> , 2008, 68, 8022-8030.	0.9	726
4	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology</i> , The, 2014, 15, 1137-1146.	10.7	382
5	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	1.6	315
6	Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225). <i>Clinical Cancer Research</i> , 2004, 10, 6487-6501.	7.0	273
7	Management of breast cancer with targeted agents: importance of heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 139-147.	27.6	143
8	Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. <i>Drugs of Today</i> , 2003, 39, 157.	2.4	141
9	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. <i>Annals of Oncology</i> , 2012, 23, 897-902.	1.2	135
10	¹⁸ F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1862-1868.	5.0	132
11	Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients. <i>Oncology</i> , 2005, 69, 35-43.	1.9	119
12	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	7.1	118
13	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	1.6	116
14	A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 6304-6312.	7.0	113
15	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	4.5	113
16	microRNAs in breast cancer development and treatment. <i>Cancer Treatment Reviews</i> , 2014, 40, 595-604.	7.7	111
17	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. <i>Annals of Oncology</i> , 2013, 24, 2715-2724.	1.2	106
18	Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. <i>Cancer</i> , 2004, 101, 133-138.	4.1	94

#	ARTICLE	IF	CITATIONS
19	Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005, 23, 6908-6918.	1.6	92
20	Targeted therapies in breast cancer: Where are we now?. <i>European Journal of Cancer</i> , 2008, 44, 2781-2790.	2.8	78
21	A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. <i>Annals of Oncology</i> , 2006, 17, 630-636.	1.2	73
22	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	7.0	73
23	Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2003, 21, 3462-3468.	1.6	72
24	Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2009, 15, 307-314.	7.0	65
25	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	2.1	61
26	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. <i>Annals of Oncology</i> , 2012, 23, 1130-1137.	1.2	60
27	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	1.6	60
28	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 858-871.	10.7	60
29	Abstract S3-3: First Results of the NeoALTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. <i>Cancer Research</i> , 2010, 70, S3-3-S3-3.	0.9	58
30	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2- α positive early breast cancer: Analysis from the NeoALTO (BIG 1-06) and ALTO (BIG 1-07) trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1000-1000.	0.1	57
31	Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. <i>Annals of Oncology</i> , 2004, 15, 1065-1071.	1.2	53
32	A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2010, 28, 3008-3008.	1.6	53
33	Survival outcomes of the NeoALTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	2.8	51
34	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 49-59.	7.0	49
35	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	2.5	49
36	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , 2008, 17, 499-505.	2.2	47

#	ARTICLE	IF	CITATIONS
37	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	4.4	47
38	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. <i>Seminars in Cancer Biology</i> , 2017, 44, 106-116.	9.6	47
39	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , 2015, 42, 887-895.	2.2	45
40	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	7.0	42
41	Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity. <i>Annals of Oncology</i> , 2000, 11, 479-481.	1.2	40
42	Heart to heart with trastuzumab: a review on cardiac toxicity. <i>Targeted Oncology</i> , 2011, 6, 189-195.	3.6	37
43	Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006, 24, 3048-3055.	1.6	35
44	Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients. <i>Cancer Investigation</i> , 2007, 25, 102-105.	1.3	35
45	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 351-357.	2.5	35
46	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma. <i>Cancer</i> , 2005, 104, 1335-1342.	4.1	34
47	Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. <i>British Journal of Cancer</i> , 2006, 94, 1789-1796.	6.4	34
48	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015, 6, 28173-28182.	1.8	34
49	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. <i>Cancer</i> , 2005, 104, 1237-1245.	4.1	33
50	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	2.2	33
51	Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. <i>British Journal of Cancer</i> , 2018, 119, 1487-1494.	6.4	33
52	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	4.1	33
53	Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. <i>Annals of Oncology</i> , 2013, 24, 1980-1985.	1.2	32
54	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020, 135, 62-65.	2.8	32

#	ARTICLE	IF	CITATIONS
55	Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3112-3112.	1.6	32
56	Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. <i>Breast</i> , 2016, 29, 90-95.	2.2	31
57	Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2021, 6, 100086.	4.5	31
58	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 133.	5.0	30
59	Phosphoinositide 3-Kinase Mutations in Breast Cancer: A “Good” Activating Mutation?. <i>Clinical Cancer Research</i> , 2009, 15, 5017-5019.	7.0	29
60	Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. <i>Breast</i> , 2013, 22, 19-23.	2.2	27
61	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 429-433.	1.8	26
62	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020, 60, 344-350.	9.6	26
63	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	3.7	26
64	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. <i>Acta Oncologica</i> , 2003, 42, 693-700.	1.8	22
65	Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 425-437.	2.5	22
66	Advancing immunotherapy for early-stage triple-negative breast cancer. <i>Lancet</i> , The, 2020, 396, 1046-1048.	13.7	20
67	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.	6.3	20
68	The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3511-3511.	1.6	20
69	Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. <i>Annals of Oncology</i> , 2003, 14, 803-804.	1.2	18
70	Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. <i>Supportive Care in Cancer</i> , 2005, 13, 375-380.	2.2	18
71	Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. <i>Tumori</i> , 2016, 102, e11-e14.	1.1	18
72	Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin. <i>Annals of Oncology</i> , 2003, 14, 1689-1690.	1.2	16

#	ARTICLE	IF	CITATIONS
73	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	3.7	16
74	Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTO trial. <i>Breast Cancer Research</i> , 2020, 22, 115.	5.0	16
75	Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. <i>Clinical Breast Cancer</i> , 2018, 18, e363-e371.	2.4	14
76	Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies. <i>Clinical Breast Cancer</i> , 2016, 16, 327-334.	2.4	13
77	The use of breast imaging for predicting response to Neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTO. <i>European Journal of Cancer</i> , 2018, 89, 42-48.	2.8	13
78	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	7.1	13
79	Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTO BIG 2-06 Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 181-189.	4.9	13
80	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	6.3	13
81	Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTO study (BIG 1-06). , 2013, , .		13
82	Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study. <i>SpringerPlus</i> , 2016, 5, 114.	1.2	12
83	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6156-6163.	7.0	12
84	Is there a benefit by the sequence anastrozole+formestane for postmenopausal metastatic breast cancer women?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 107-109.	2.5	11
85	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	2.8	11
86	Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. <i>Medical Oncology</i> , 2019, 36, 4.	2.5	11
87	CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer. <i>Breast</i> , 2021, 55, 75-78.	2.2	11
88	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.7	10
89	HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature. <i>Breast Care</i> , 2016, 11, 424-426.	1.4	10
90	Trastuzumab Cardiac Toxicity: A Problem we Put our Heart Into. <i>Tumori</i> , 2016, 102, 1-5.	1.1	10

#	ARTICLE	IF	CITATIONS
91	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 1470.	3.3	10
92	Management of the axilla in early breast cancer patients in the genomic era. <i>Annals of Oncology</i> , 2013, 24, 1163-1170.	1.2	9
93	Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. <i>Breast Care</i> , 2017, 12, 391-394.	1.4	9
94	Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian Experience. <i>Clinical Breast Cancer</i> , 2018, 18, e1059-e1066.	2.4	9
95	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	5.2	9
96	Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer – Moving beyond pathological complete response. <i>Breast</i> , 2014, 23, 188-192.	2.2	8
97	Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. <i>Medical Oncology</i> , 2018, 35, 107.	2.5	8
98	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021, 13, 1324.	3.7	8
99	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	7.0	8
100	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 512-512.	1.6	8
101	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, 574-574.	1.6	8
102	Catheter-Related Bloodstream Infections, Part I: Pathogenesis, Diagnosis, and Management. <i>Cancer Control</i> , 2002, 9, 513-523.	1.8	7
103	Axillary Coverage by Whole Breast Irradiation in 1 to 2 Positive Sentinel Lymph Nodes in Breast Cancer Patients. <i>Tumori</i> , 2016, 102, 409-413.	1.1	7
104	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020, 12, 3509.	3.7	7
105	Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). <i>Journal of Clinical Oncology</i> , 2004, 22, 3074-3074.	1.6	7
106	Subacute motor weakness and left renal mass. <i>American Journal of Medicine</i> , 2003, 114, 706-708.	1.5	6
107	Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma. <i>Tumori</i> , 2005, 91, 103-103.	1.1	6
108	Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?. <i>Annals of Oncology</i> , 2005, 16, 1209-1210.	1.2	6

#	ARTICLE	IF	CITATIONS
109	P124 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 1-06/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC). Breast, 2007, 16, S48.	2.2	6
110	Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. Breast, 2014, 23, 690-691.	2.2	6
111	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS ONE, 2019, 14, e0220644.	2.5	6
112	Interobserver variability (between radiation oncologist and radiation therapist) in tumor bed contouring after breast-conserving surgery. Tumori, 2019, 105, 210-215.	1.1	6
113	Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). Journal of Clinical Oncology, 2004, 22, 3074-3074.	1.6	6
114	What if the future of HER2 ⁺ positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine, 2022, 11, 332-339.	2.8	6
115	Gastric Stump Lymphoma Five Years After Distal Gastrectomy. Leukemia and Lymphoma, 2003, 44, 365-367.	1.3	5
116	HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear?. Journal of Clinical Oncology, 2004, 22, 568-569.	1.6	5
117	Effect of Filgrastim on Serum Lactate Dehydrogenase and Alkaline Phosphatase Values in Early Breast Cancer Patients. Cancer Investigation, 2004, 22, 650-653.	1.3	5
118	Pharmacodynamic endpoints in primary breast cancer. Annals of Oncology, 2007, 18, ix21-ix23.	1.2	5
119	Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. Breast Cancer Research, 2009, 11, S25.	5.0	5
120	Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study. Breast Cancer, 2017, 24, 635-641.	2.9	5
121	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. Breast, 2017, 35, 63-68.	2.2	5
122	Older age and comorbidity in breast cancer: is RT alone the new therapeutic frontier?. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1791-1800.	2.5	5
123	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	7.0	5
124	SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2012, 30, 1011-1011.	1.6	5
125	Covid-19 outbreak in Lombardy: impact on reducing solid cancer diagnoses in 2020. International Journal of Cancer, 0, , .	5.1	5
126	Breast Cancer Metastatic to the Choroid in a Male Patient Case Report. Tumori, 2003, 89, 333-335.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Exploratory phase II study of celecoxib and infusional fluorouracil as second-line treatment for advanced pancreatic (PDAC) and biliary tree cancer (BTC). Journal of Clinical Oncology, 2004, 22, 4183-4183.	1.6	4
128	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 2016, 7, 67956-67965.	1.8	4
129	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. Npj Breast Cancer, 2022, 8, .	5.2	4
130	Catheter-Related Bloodstream Infections, Part II: Specific Pathogens and Prevention. Cancer Control, 2003, 10, 79-91.	1.8	3
131	5013 ORAL FDG-PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-positive Breast Cancer Patients: the Neo-ALTTO Study Results. European Journal of Cancer, 2011, 47, S333-S334.	2.8	3
132	Prognosis of women with early breast cancer and PIK3CA mutations. Breast, 2015, 24, 283-284.	2.2	3
133	Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients. Breast, 2018, 40, 131-135.	2.2	3
134	Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial. Annals of Oncology, 2019, 30, iii28-iii29.	1.2	3
135	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160.	3.2	3
136	Hypofractionated irradiation in 794 elderly breast cancer patients: An observational study. Breast Journal, 2020, 26, 188-196.	1.0	3
137	VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30ÂGy in five daily fractions. Clinical and Translational Oncology, 2020, 22, 1802-1808.	2.4	3
138	Automated breast ultrasound compared to hand-held ultrasound in surveillance after breast-conserving surgery. Tumori, 2021, 107, 132-138.	1.1	3
139	Abstract P1-09-09: Efficacy and gene expression results from SOLT1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3
140	Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). Journal of Clinical Oncology, 2007, 25, 1066-1066.	1.6	3
141	Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients.. Journal of Clinical Oncology, 2010, 28, 628-628.	1.6	3
142	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2â€positive and ERâ€positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular Oncology, 2022, 16, 2355-2366.	4.6	3
143	Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. , 2022, 10, e004820.		3
144	Can Colorectal Cancer Patients With Thymidylate Synthaseâ€“Overexpressing Liver Metastases Have an Overall Survival Advantage With Hepatic Arterial Infusion Alone?. Journal of Clinical Oncology, 2003, 21, 3543-3544.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. <i>Breast</i> , 2006, 15, 269-272.	2.2	2
146	Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. <i>Clinical Oncology</i> , 2014, 26, 174.	1.4	2
147	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , 2015, 17, 530-538.	2.4	2
148	Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.. <i>European Journal of Cancer</i> , 2020, 138, S15-S16.	2.8	2
149	Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. <i>Frontiers in Oncology</i> , 2020, 10, 1223.	2.8	2
150	Hypofractionated whole-breast radiotherapy in large breast size patients: is it really a resolved issue?. <i>Medical Oncology</i> , 2021, 38, 107.	2.5	2
151	Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer â€œ NeoPHOEBE. <i>Cancer Research</i> , 2013, 73, OT2-6-08-OT2-6-08.	0.9	2
152	Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10067-10067.	1.6	2
153	Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1543-1550.	2.5	2
154	Suspected Pharmacological Interactions in a Cancer Patient During Methadone Maintenance. <i>Addictive Disorders and Their Treatment</i> , 2004, 3, 87-92.	0.5	1
155	Correlation Between Circulating Tumor Cells (CTCS), PET/CT Response And Pathological Complete Response (PCR) in Primary HER2-Positive (HER2+) Breast Cancer Patients: A Sub-Study From the Neoalto Trial. <i>Annals of Oncology</i> , 2012, 23, ix98.	1.2	1
156	The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoalto Trial (BIG 1-06). <i>Annals of Oncology</i> , 2012, 23, ix4.	1.2	1
157	Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1912-1912.	6.3	1
158	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , 2016, 27, 187-188.	2.2	1
159	Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice. <i>Annals of Oncology</i> , 2019, 30, v718.	1.2	1
160	Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 786-792.	2.4	1
161	59P Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC). <i>Annals of Oncology</i> , 2020, 31, S35-S36.	1.2	1
162	Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2020, 31, 435-437.	1.2	1

#	ARTICLE	IF	CITATIONS
163	P5-13-01: Survival Outcome with Bevacizumab: Activation of the Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA Mutations or PTEN Loss Makes a Difference.. , 2011, , .		1
164	Abstract P3-07-66: Efficacy and gene expression results from eribulin SOLT11007 neoadjuvant study. , 2016, , .		1
165	A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS625-TPS625.	1.6	1
166	Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m2 of doxorubicin (D).. Journal of Clinical Oncology, 2010, 28, 1112-1112.	1.6	1
167	Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.. Journal of Clinical Oncology, 2018, 36, 577-577.	1.6	1
168	Long-Term Follow-Up in Breast Cancer Survivors: A Single Institution Survey. Journal of Women's Health, 2003, 12, 599-600.	3.3	0
169	Fatal Thrombocytopenia and Thrombocytopathia: An Unusual Onset of Non-Small Cell Lung Cancer. Oncology Research and Treatment, 2003, 26, 272-274.	1.2	0
170	Correction: Article on TLC-D99, Paclitaxel, Trastuzumab in HER-2 Breast Cancer. Clinical Cancer Research, 2009, 15, 1843-1843.	7.0	0
171	5064 POSTER Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab. European Journal of Cancer, 2011, 47, S349.	2.8	0
172	1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. European Journal of Cancer, 2015, 51, S269.	2.8	0
173	It's not the quality but the quantity: tumor mutation spectrum and response to neoadjuvant therapy in triple negative breast cancer. Annals of Oncology, 2016, 27, iv70.	1.2	0
174	Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial. Annals of Oncology, 2016, 27, vi57.	1.2	0
175	Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated. Annals of Oncology, 2016, 27, vi49.	1.2	0
176	Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history. Breast Cancer, 2017, 24, 491-492.	2.9	0
177	PO-0662: Target therapy and hypofractionated whole breast radiotherapy: an unexpected protective factor. Radiotherapy and Oncology, 2017, 123, S345-S346.	0.6	0
178	Time to surgery after neoadjuvant chemotherapy for early breast cancer. Annals of Oncology, 2017, 28, vi29.	1.2	0
179	Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial. Annals of Oncology, 2017, 28, v50.	1.2	0
180	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoSphere study. European Journal of Cancer, 2018, 92, S8.	2.8	0

#	ARTICLE	IF	CITATIONS
181	Multicenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study. <i>Annals of Oncology</i> , 2019, 30, v124-v125.	1.2	0
182	EP-1284 Older age and comorbidity in breast cancer: is radiotherapy alone the new therapeutic frontier?. <i>Radiotherapy and Oncology</i> , 2019, 133, S703-S704.	0.6	0
183	EP-1285 Hypofractionated irradiation in elderly breast cancer patients: an observational study. <i>Radiotherapy and Oncology</i> , 2019, 133, S704.	0.6	0
184	RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1232-1233.	6.3	0
185	Gene Profiles in Breast Cancer. , 2019, , 351-361.		0
186	High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer. <i>Tumori</i> , 2020, 106, 64-69.	1.1	0
187	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	7.2	0
188	153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials. <i>Annals of Oncology</i> , 2020, 31, S71.	1.2	0
189	Nobody dares stopping clinical research, not even COVID-19. <i>Npj Breast Cancer</i> , 2021, 7, 39.	5.2	0
190	Timing of adjuvant chemotherapy by menstrual cycle phase and risk of secondary amenorrhea in women with early breast cancer: Preliminary results. <i>Journal of Clinical Oncology</i> , 2004, 22, 780-780.	1.6	0
191	Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters?. <i>Journal of Clinical Oncology</i> , 2009, 27, e20527-e20527.	1.6	0
192	Timing of re-excision surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (aRx) in early breast cancer patients (BC pts).. <i>Journal of Clinical Oncology</i> , 2010, 28, e11065-e11065.	1.6	0
193	Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).. <i>Journal of Clinical Oncology</i> , 2010, 28, 1113-1113.	1.6	0
194	Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 1081-1081.	1.6	0
195	Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A).. <i>Journal of Clinical Oncology</i> , 2011, 29, 1074-1074.	1.6	0
196	P5-11-12: Correlation of Ki67 Expression between Initial Biopsy and Surgical Specimen in Untreated Breast Cancer Patients. Does Menstrual Cycle Matter?. , 2011, , .		0
197	P3-07-21: Sentinel Lymph Node Metastasis Are More Likely To Develop in Triple Positive Breast Cancer Patients without Compromising Disease Free Survival.. , 2011, , .		0
198	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2012, 30, 619-619.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Abstract OT3-3-06: NeoEribulin: A Phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer.. , 2012, , .		0
200	Abstract P4-12-22: Time to relapse (TTR) is a potential discriminator of clinical outcome in HER2-positive breast cancer (BC) patients (pts) progressing on adjuvant trastuzumab (AdjT). , 2013, , .		0
201	HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression.. Journal of Clinical Oncology, 2014, 32, e11591-e11591.	1.6	0
202	The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies.. Journal of Clinical Oncology, 2014, 32, e11565-e11565.	1.6	0
203	Abstract P1-14-22: Neo-adjuvant chemotherapy for the treatment of breast cancer exerts a selection pressure toward luminal phenotype. , 2016, , .		0
204	Abstract P2-06-07: Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment. , 2017, , .		0
205	Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO. , 2017, , .		0
206	Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG) Tj ETQq0.0 0 rgBT0Overlock		0
207	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	1.6	0
208	Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population.. Journal of Clinical Oncology, 2019, 37, e16087-e16087.	1.6	0
209	Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial. , 2019, , .		0
210	Fixed dose-rate gemcitabine (GEM) infusion in advanced pancreatic (PDAC) and biliary tree (BTC) carcinoma: A phase II study. Journal of Clinical Oncology, 2004, 22, 4182-4182.	1.6	0
211	Brain metastases in HER2-positive breast cancer: challenges and opportunities. Annals of Palliative Medicine, 2012, 1, 195-7.	1.2	0